BRUSSELS, BELGIUM & SAN FRANCISCO, USA – April 20, 2026 – Global biopharmaceutical leader UCB has finalized a definitive agreement…
Read More

BRUSSELS, BELGIUM & SAN FRANCISCO, USA – April 20, 2026 – Global biopharmaceutical leader UCB has finalized a definitive agreement…
Read More
Over the past 16 months, Chinese-domiciled biotechnology companies have emerged as formidable forces in the global pharmaceutical landscape, featuring prominently…
Read More
The global pharmaceutical market for obesity treatments is poised for a dramatic transformation, with a burgeoning segment of non-Glucagon-like peptide-1…
Read More
Boehringer Ingelheim has officially launched a new, state-of-the-art Artificial Intelligence (AI) and Machine Learning (ML) center in London’s King’s Cross,…
Read More
In a significant move poised to reshape the landscape of mental health treatment, U.S. President Donald Trump has signed an…
Read More
Eli Lilly and Company has officially claimed the top position in the global pharmaceutical industry by revenue for fiscal year…
Read More
Boehringer Ingelheim and Zai Lab have announced a significant clinical collaboration aimed at investigating a dual delta-like ligand 3 (DLL3)-targeting…
Read More
The pharmaceutical industry’s financial landscape underwent a significant transformation in fiscal year 2025, revealing a nuanced shift in leadership despite…
Read More
A comprehensive review of 17 clinical trials by the esteemed Cochrane organization has cast doubt on the clinically meaningful benefits…
Read More
The pharmaceutical landscape in Fiscal Year 2025 was defined by a monumental shift at the very apex of the industry’s…
Read More